en · de · es
sr9009-notes.peptides7501.com › Faq › Mechanism And Preclinical Findings — Evidence Review

Mechanism And Preclinical Findings — Evidence Review

By Editorial Desk · published 2026-07-22 · last reviewed 2026-08-01 · Faq

A practical reference on anti-doping: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.

Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.

Mechanism and Preclinical Findings

Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.

The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.

Background and Receptor Pharmacology

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.

Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.

Sr9009 at a glance

PropertyValueNotes
Chemical classSynthetic REV-ERB agonistSmall molecule; not a steroid or peptide.
Primary targetsNR1D1 and NR1D2Also known as REV-ERBα and REV-ERBβ.
Studied routesIntraperitoneal in rodentsOral bioavailability in humans is not established.
Human approvalNo approved therapeutic indicationNo recognized clinical use.
Key uncertaintyHuman physiological effectsPreclinical findings may not translate.

Handling Storage and Quality Control

Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.

Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.

Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.

Related pages on this site

Regulation, Testing, and Storage

Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.

Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.

SR9009 Identity and Mechanism

SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.

SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.

REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.

Notes from published material

=== EC 1.14.15 With reduced iron–sulfur protein as one donor, and incorporation of one atom of oxygen === EC 1.14.15.1: camphor 5-monooxygenase EC 1.14.15.2: Now EC 1.14.13.162, 2,5-diketocamphane 1,2-monooxygenase. EC 1.14.15.3: alkane 1-monooxygenase EC 1.14.15.4: steroid 11β-monooxygenase EC 1.14.15.5: corticosterone 18-monooxygenase EC 1.14.15.6: cholesterol monooxygenase (side-chain-cleaving) EC 1.14.15.7: choline monooxygenase EC 1.14.15.8: steroid 15β-monooxygenase EC 1.14.15.9: spheroidene monooxygenase EC 1.14.15.10: (+)-camphor 6-endo-hydroxylase EC 1.14.15.11: pentalenic acid synthase EC 1.14.15.12 : pimeloyl-[acyl-carrier protein] synthase.

=== Location and Position === The apical foramen is the principal opening at a tooth's root terminus, serving as the conduit between the root canal system and the periapical tissues. Its location is variable, as it frequently deviates from the anatomical apex—the root's geometric tip. Studies indicate that in a majority of cases, the foramen is positioned laterally, most commonly on the distal aspect. The average deviation is typically less than 1 millimeter, though greater distances are observed in specific teeth such as mandibular canines and molars. The foramen's morphology is often oval but can be circular or irregular. Its precise location and shape can be influenced by ethnic background, age, and physiological changes. In clinical endodontics, accurate identification of the apical foramen, rather than reliance on the radiographic apex alone, is essential for determining the correct working length and ensuring treatment success.

=== Substrate binding === Creatine binds inside the β-half-barrel trough of the large C-terminal domain, forming hydrogen bonds between its amidino and carboxyl groups and the enzyme's amino-acid residues. A metal ion, either Zn2+ or Mn2+, is used to stabilize the substrate and polarize the amidino group.

Sources: en.wikipedia.org

Background from the literature

The road currently visible presents the last state of its construction in the Later Roman Empire around the 4th century. It was made using large slabs of Cassis stone, very resistant to the traffic of heavy carts. The wide grooves are still visible. They were made to prevent the wheels from slipping, while the holes visible in the middle of the slabs were intended for handling and positioning them. On the edges of the roadway, there is a sidewalk.

Adult linear IgA disease Bullous pemphigoid Bullous lupus erythematosus Childhood linear IgA disease (chronic bullous disease of childhood) Cicatricial pemphigoid (benign mucosal pemphigoid, benign mucous membrane pemphigoid, ocular pemphigus, scarring pemphigoid) Dermatitis herpetiformis (Duhring disease) Dyshidrosis (recurrent vesicular palmoplantar dermatitis, acute vesiculobullous hand eczema, dyshidrotic dermatitis, pompholyx) Endemic pemphigus (endemic pemphigus foliaceus, fogo selvagem) Epidermolysis bullosa acquisita Grover's disease (benign papular acantholytic dermatosis, persistent acantholytic dermatosis, transient acantholytic dermatosis) IgA pemphigus Intraepidermal neutrophilic IgA dermatosis Localized cicatricial pemphigoid (Brunsting–Perry cicatricial pemphigoid) Paraneoplastic pemphigus Pemphigus erythematosus (Senear–Usher syndrome) Pemphigus foliaceus Pemphigus herpetiformis (acantholytic herpetiform dermatitis, herpetiform pemphigus, mixed bullous disease, pemphigus controlled by sulfapyridine) Pemphigoid nodularis Pemphigus vegetans Pemphigus vegetans of Hallopeau Pemphigus vegetans of Neumann Pemphigus vulgaris Vesicular pemphigoid Vulvar childhood pemphigoid

The PDE5 inhibitors sildenafil (Viagra), vardenafil (Levitra) and tadalafil (Cialis) are prescription drugs which are taken by mouth. As of 2018, sildenafil is available in the UK without a prescription. Additionally, a cream combining alprostadil with the permeation enhancer DDAIP has been approved in Canada as a first line treatment for ED. Penile injections, on the other hand, can involve one of the following medications: papaverine, phentolamine, and prostaglandin E1, also known as alprostadil. In addition to injections, there is an alprostadil suppository that can be inserted into the urethra. Once inserted, an erection can begin within 10 minutes and last up to an hour. Medications to treat ED may cause a side effect called priapism.

Sources: en.wikipedia.org

Reference notes

With insect infestation common in improperly stored provisions, soldiers would break up the hardtack and drop it into their morning coffee. This would not only soften the hardtack but the insects, mostly weevil larvae, would float to the top, and the soldiers could skim them off and eat the biscuits. The grubs "left no distinctive flavor behind." Some men turned hardtack into a mush by breaking it up with blows from their rifle butts, then adding water. If the men had a frying pan, they could cook the mush into a lumpy pancake; otherwise they dropped the mush directly on the coals of their campfire. They also mixed hardtack with brown sugar, hot water, and sometimes whiskey to create what they called a pudding, to serve as dessert.

== Challenges and limits == Measuring beta-cell function requires the rate of secretion to be interpreted in relation to the prevailing glucose concentration. Therefore, a mathematical model is needed that links the time courses of insulin secretion and glucose concentration as a mechanistic causal relationship.

=== Superhydrophobic surfaces === A superhydrophobic surface is a low energy, generally rough surface on which water has a contact angle of >150°. Nonpolar materials such as hydrocarbons traditionally have relatively low surface energies, however, this property alone is insufficient to achieve superhydrophobicity. Superhydrophobic surfaces can be created in many ways, however, most of the synthesis strategies are inspired by natural designs. The Cassie-Baxter model provides an explanation for superhydropbicity—air trapped in microgrooves of a rough surface creates a "composite" surface consisting of air and the tops of microprotrusions. This structure is maintained as the scale of the features decreases, thus many approaches to the synthesis of superhydrophobic surfaces have focused on the fractal contribution. Wax solidification, lithography, vapor deposition, template methods, polymer reconfirmation, sublimation, plasma, electrospinning, sol-gel processing, electrochemical methods, hydrothermal synthesis, layer-by-layer deposition, and one-pot reactions are approaches to the creation of superhydrophobic surfaces that have been suggested. Making a surface superhydrophobic represents an efficient means of imparting antimicrobial activity. A passive antibacterial effect results from the poor ability of microbes to adhere to the surface. The area of superhydrophobic textiles takes advantage of this and could have potential applications as antimicrobial coatings.

Some historians state that the repression and totalitarianism came from Marxist–Leninist ideology. Others offer different explanations and criticise focus on the upper levels of society, and concepts such as totalitarianism, which obscure the reality of the system. While the emergence of the Soviet Union as the first nominally communist state led to communism's association with Marxism–Leninism and the Soviet model, several academics say that Marxism–Leninism in practice was a form of state capitalism. The socio-economic nature of communist states, especially of the Soviet Union during the Stalin era (1924–53), has been much debated, varyingly being labelled a form of bureaucratic collectivism, state capitalism, state socialism, or a unique mode of production. The Eastern Bloc, including communist states in Central and Eastern Europe as well as the Third World socialist regimes, have been described as "bureaucratic-authoritarian systems", and China's socio-economic structure has been referred to as "nationalistic state capitalism".

Sources: en.wikipedia.org

Frequently asked questions

What is SR9009?

It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.

How does SR9009 differ from typical receptor agonists?

REV-ERB receptors generally repress transcription when bound by natural heme. SR9009 is described as an agonist that enhances this repressive activity. The result is altered expression of clock and metabolic genes.

Has SR9009 been tested in humans?

Published controlled human trials are lacking. Some sources cite limited or unofficial reports, but these do not establish safety or efficacy. Claims about human performance effects remain unverified.

What is SR9009?

SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.

Network